Point of Care Diagnostics Market by Product (Glucose, Infectious Disease [TB, HAI, STD], Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx [RT-PCR, INAAT]), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2031

Market Size
$20.63B
MARKET SIZE, 2026
Projected Market Size
$31.46B
MARKET SIZE, 2031
CAGR
8.8%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

POINT OF CARE DIAGNOSTICS MARKET SIZE, SHARE & GROWTH SNAPSHOT

point-of-care-diagnostic-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global point of care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at a CAGR of 8.8% during the forecast period. The market was valued at USD 19.38 billion in 2025. Revenue growth in the point-of-care (POC) diagnostics market is increasingly shifting toward decentralized, portable, and digitally connected diagnostic solutions that enable faster clinical decision-making and improved disease management. The rising prevalence of chronic and infectious diseases, including diabetes, cardiovascular diseases, respiratory disorders, and infectious illnesses, is expanding demand for rapid and accurate diagnostic testing across healthcare settings. Market opportunities are further shifting from traditional centralized testing models toward near-patient and home-based testing solutions, supported by increasing healthcare utilization and the growing need for timely diagnosis. Additionally, continuous advancements in portable diagnostic technologies, digital health integration, and connectivity-enabled platforms are accelerating the adoption of POC diagnostics across hospitals, clinics, and community healthcare environments.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2025): USD 19.38 Billion
    Current Market Size (2026): USD 20.63 Billion
    Forecast Market Size (2031): USD 31.46 Billion
    CAGR (2026–2031): 8.8%
  • SEGMENT LEADERSHIP:
    Regional Outlook: China is expected to register the highest CAGR of 11.1% during the forecast period.
    Product Leader: Glucose monitoring products held 34.8% of the market in 2025.
    End User Insight: Home care settings and self-testing market was valued at USD 6,936.5 million in 2025.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), and Becton, Dickinson and Company (BD) (US) were identified as Star Players due to their strong focus on innovation, extensive product portfolios, broad industry presence, and robust operational and financial capabilities.
    Visby Medical (US), Cue Health (US), and Truvian Health (US) are among a few key startups and SMEs due to their strong product portfolio and business strategies.

Rapid improvements in healthcare infrastructure across emerging economies are significantly contributing to the growth of the point-of-care (POC) diagnostics market. Governments and private healthcare providers are expanding investments in hospitals, primary healthcare centers, diagnostic laboratories, and community health facilities to strengthen access to timely diagnostic services. These initiatives are improving healthcare delivery and encouraging the adoption of rapid, portable, and easy-to-use point-of-care diagnostic solutions. Additionally, increasing healthcare expenditure, expanding health insurance coverage, and ongoing digital health initiatives are supporting broader access to diagnostic testing across urban and rural settings. The growing emphasis on early disease detection, decentralized healthcare delivery, and improved patient outcomes is driving the integration of point-of-care diagnostics into routine clinical practice.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The point-of-care diagnostics market is evolving from conventional laboratory-based testing toward rapid, decentralized, and patient-centric diagnostic solutions that enable faster clinical decision-making across hospitals, clinics, home care, and remote settings. Rising demand for early disease detection, immediate test results, and accessible healthcare is driving the adoption of portable, user-friendly, and minimally invasive diagnostic devices. Advances in digital health technologies, AI-enabled diagnostics, smartphone connectivity, and cloud-based data management are transforming point-of-care testing by improving accuracy, efficiency, and real-time clinical insights. As healthcare providers increasingly prioritize timely diagnosis, personalized treatment, and decentralized care delivery, manufacturers are focusing on compact platforms, multiplex testing capabilities, strategic collaborations, and integrated digital ecosystems. The growing shift toward home-based testing, remote patient management, and connected healthcare infrastructure is further accelerating innovation and expanding the adoption of point-of-care diagnostics worldwide.

point-of-care-diagnostic-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising prevalence of chronic and infectious diseases
  • Increasing demand for rapid diagnosis and immediate clinical decision-making
RESTRAINTS
Impact
Level
  • Stringent regulatory requirements for diagnostic device approval
  • High costs associated with advanced POC diagnostic technologies
OPPORTUNITIES
Impact
Level
  • Growing demand for home-based and decentralized diagnostic testing
  • Expansion of AI-enabled and digital POC diagnostic solutions
CHALLENGES
Impact
Level
  • Pricing pressure from low-cost and conventional lab testing
  • Limited healthcare infrastructure and skilled personnel in developing regions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising prevalence of chronic and infectious diseases

The increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, cancer, and respiratory diseases, along with the growing burden of infectious diseases, is a major driver for the point-of-care diagnostics market. Patients with these conditions require rapid and frequent diagnostic testing for early detection, disease management, and timely treatment decisions. The rising demand for decentralized healthcare, coupled with an aging population and increasing healthcare expenditures, is accelerating the adoption of point-of-care diagnostic solutions. Additionally, healthcare providers are increasingly utilizing rapid diagnostic tests to improve clinical outcomes, reduce hospital stays, and enhance patient convenience, further supporting market growth.

Restraint: Stringent regulatory requirements for diagnostic device approval

One of the major restraints in the POC diagnostics market is the stringent regulatory approval process for diagnostic devices. Manufacturers must comply with rigorous clinical validation, quality assurance, and performance standards before commercialization, which increases development costs and extends product launch timelines. Variations in regulatory requirements across different countries further complicate global market entry. As a result, these regulatory challenges can delay innovation and limit the availability of new point-of-care diagnostic technologies.

Opportunity: Growing demand for home-based and decentralized diagnostic testing

The increasing shift toward home-based healthcare and decentralized testing presents a significant opportunity in this market. Patients and healthcare providers are increasingly adopting portable diagnostic devices that deliver rapid and accurate results outside traditional laboratory settings. The expansion of telehealth services, digital health platforms, and connected diagnostic solutions is further supporting this trend by enabling remote disease monitoring and timely clinical intervention. Continuous advancements in portable testing platforms, smartphone-enabled diagnostics, and AI-assisted interpretation are expected to create substantial growth opportunities for market participants.

Challenge: Pricing pressure from low-cost and conventional laboratory testing

The widespread availability of low-cost laboratory testing and affordable diagnostic alternatives presents a key challenge for manufacturers of point-of-care diagnostic devices. Many healthcare providers continue to rely on centralized laboratory testing due to established workflows, economies of scale, and lower per-test costs. In price-sensitive markets, budget constraints may limit the adoption of advanced point-of-care diagnostic systems despite their clinical advantages. Additionally, manufacturers face increasing pressure to offer high-performance diagnostic solutions at competitive prices while maintaining quality, regulatory compliance, and continuous product innovation.

POINT OF CARE DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Develops a broad portfolio of point-of-care diagnostic solutions, including rapid infectious disease testing, cardiac biomarkers, blood glucose monitoring, and handheld diagnostic analyzers for hospitals, clinics, and home care settings. Enables rapid diagnosis, supports timely clinical decision-making, improves patient outcomes, and reduces turnaround time in emergency and primary care settings.
Provides point-of-care diagnostic systems for blood glucose monitoring, coagulation testing, infectious diseases, and molecular diagnostics, supporting hospitals, laboratories, and decentralized healthcare environments. Delivers accurate and reliable diagnostic results, enhances disease management, improves workflow efficiency, and facilitates faster treatment decisions.
Offers molecular point-of-care diagnostic platforms for rapid detection of infectious diseases, antimicrobial resistance, and critical healthcare conditions using automated PCR technologies. Enables highly accurate and rapid molecular testing, reduces laboratory turnaround time, supports infection control, and improves patient management.
Provides point-of-care diagnostic analyzers for blood gas, cardiac markers, coagulation, and clinical chemistry testing across emergency departments, intensive care units, and outpatient facilities. Improves diagnostic efficiency, delivers fast and precise test results, supports critical care decision-making, and enhances operational productivity.
Manufactures rapid point-of-care diagnostic solutions for respiratory infections, COVID-19, influenza, strep, and immunoassay testing for physician offices, urgent care centers, and hospitals. Supports quick disease detection, enables immediate treatment decisions, improves patient throughput, and enhances healthcare accessibility through decentralized testing.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The ecosystem of the POC diagnostics market comprises diagnostic device manufacturers, reagent and consumable suppliers, software and connectivity providers, contract development and manufacturing organizations (CDMOs), distributors, research institutions, regulatory bodies, and healthcare providers. The market includes rapid diagnostic solutions such as molecular diagnostics, immunoassays, blood glucose monitoring systems, blood gas analyzers, cardiac biomarker tests, coagulation analyzers, and infectious disease testing platforms, supported by portable analyzers, digital health platforms, and data management software. Manufacturers focus on product innovation, assay development, regulatory approvals, and commercialization, while distributors ensure product availability across hospitals, clinics, diagnostic laboratories, pharmacies, urgent care centers, ambulatory care facilities, and home healthcare settings. The ecosystem is further strengthened by advancements in AI-enabled diagnostics, connectivity solutions, and multiplex testing, with government agencies, reimbursement bodies, and public health organizations driving adoption, regulatory compliance, and market expansion.

point-of-care-diagnostic-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

point-of-care-diagnostic-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Point of Care Diagnostics Market, by Product

The glucose monitoring products segment includes blood glucose meters, test strips, lancets, continuous glucose monitoring (CGM) systems, and related accessories, accounting for a significant share of the market due to the increasing prevalence of diabetes and the growing adoption of self-monitoring and continuous glucose monitoring technologies. Other major product categories include cardiometabolic monitoring products for cardiovascular and metabolic health assessment, infectious disease testing products for rapid and laboratory-based pathogen detection, coagulation monitoring products for blood clotting analysis, pregnancy & fertility testing products for reproductive health monitoring, tumor/cancer marker testing products for oncology diagnostics, urinalysis testing products for kidney and urinary tract assessment, cholesterol testing products for lipid profiling, hematology testing products for complete blood count and related analyses, drugs-of-abuse testing products for toxicology screening, thyroid stimulating hormone (TSH) testing products for thyroid function evaluation, and fecal occult testing products for colorectal disease screening. The increasing demand for point-of-care diagnostics, preventive healthcare, home-based testing solutions, and technological advancements in diagnostic devices is further driving the growth of the diagnostic testing products market.

Point of Care Diagnostics Market, by End User

The hospitals, critical care centers, and urgent care centers segment holds a significant market share due to the high demand for rapid diagnostic testing and timely clinical decision-making. Clinical laboratories remain key end users for routine and specialized diagnostic testing, while ambulatory care facilities and physician offices are increasingly adopting point-of-care diagnostics to improve patient management and reduce turnaround time. The home care settings & self-testing segment is witnessing strong growth, driven by the rising adoption of self-testing kits, increasing prevalence of chronic diseases, and growing preference for convenient home-based healthcare. Other end users include retail clinics, community health centers, and research institutions.

REGION

Healthcare Infrastructure Expansion Driving Growth in the Asia Pacific Point-of-Care Diagnostics Market

The POC diagnostics market across the Asia Pacific is rapidly evolving, driven by economic growth, increasing healthcare expenditure, and a stronger government focus on improving access to timely disease diagnosis. Countries such as India, China, and Indonesia are investing significantly in strengthening primary healthcare infrastructure, expanding diagnostic capabilities, and improving access to decentralized testing services. The establishment of community health centers, rural clinics, and modern hospitals is increasing the adoption of point-of-care diagnostic technologies, enabling rapid testing for infectious diseases, chronic conditions, and emergency care. Additionally, private healthcare providers are increasingly investing in digital diagnostics, connected testing platforms, and integrated healthcare solutions to enhance clinical decision-making and patient outcomes. With continued healthcare infrastructure development and growing emphasis on early disease detection, the procurement of point-of-care diagnostic products such as blood glucose meters, rapid diagnostic tests (RDTs), HbA1c analyzers, cardiac marker testing systems, blood gas analyzers, and handheld molecular diagnostic devices is increasing, making healthcare infrastructure expansion a key driver of growth for the Asia Pacific point-of-care diagnostics market.

point-of-care-diagnostic-market Region

POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX

In the point-of-care diagnostics market, Abbott (Star Player) leads with its comprehensive portfolio of rapid diagnostic solutions and strong global presence, while EKF Diagnostics (Emerging Leader) is strengthening its position through innovation in near-patient testing technologies and specialized point-of-care diagnostic solutions.

point-of-care-diagnostic-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • QuidelOrtho Corporation
  • Danaher
  • Becton, Dickinson, and Company
  • Thermo Fisher Scientific, Inc.
  • bioMérieux
  • EKF Diagnostics
  • QIAGEN
  • Werfen S.A
  • OraSure Technologies
  • Trinity Biotech
  • Grifols S.A
  • Nova Biomedical
  • Sekisui Diagnostics
  • Trividia Health
  • Sysmex Corporation
  • HemoCue
  • Bio-Rad Laboratories
  • Chembio Diagnostics
  • Johnson & Johnson
  • LifeScan
  • Ascensia Diabetes Care
  • ARKRAY
  • Sinocare
  • Wondfo Biotech

MARKET SCOPE

REPORT METRIC DETAILS
Base Year 2025
Base Year Market Size (2025) USD 19.38 Billion
Current Market Size (2026) USD 20.63 Billion
Projected Market Size (2031) USD 31.46 Billion
Growth Rate CAGR of 8.8% from 2026–2031
Forecast Period 2026–2031
Years Considered 2024–2031
Units Considered Value (USD BN), Volume (Thousand Units)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered By Product, Mode of Purchase, Technology, Sample, End User, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Report Code MD 2702
Published 2026-07-10
Prepared By MarketsandMarkets™ Healthcare Research Team
Last Reviewed 2026-07-24

WHAT IS IN IT FOR YOU: POINT OF CARE DIAGNOSTICS MARKET REPORT CONTENT GUIDE

point-of-care-diagnostic-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis Comparative analysis of point-of-care diagnostic technologies by product type, including glucose monitoring systems, infectious disease testing kits, cardiac biomarker tests, blood gas & electrolyte analyzers, coagulation testing devices, pregnancy & fertility tests, urinalysis, HbA1c analyzers, molecular diagnostics, rapid antigen tests, and multiplex diagnostic platforms, along with evaluation across hospitals, emergency departments, physician offices, clinics, pharmacies, homecare, and decentralized healthcare settings. Assessment of diagnostic performance through parameters such as sensitivity, specificity, turnaround time, portability, ease of use, connectivity, CLIA-waived capabilities, AI integration, workflow efficiency, cost-effectiveness, and regulatory compliance to support optimal product selection and improved clinical outcomes.
Company Information Detailed profiles of leading global and regional point-of-care diagnostics manufacturers, including Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher (Cepheid, Beckman Coulter), bioMérieux, BD, QuidelOrtho, Thermo Fisher Scientific, Sysmex, EKF Diagnostics, and Nova Biomedical, covering product portfolios, diagnostic technologies, strategic initiatives, geographic presence, partnerships, regulatory approvals, and recent product developments. Competitive benchmarking across key players highlighting positioning by technological innovation, test menu breadth, molecular diagnostics capabilities, digital connectivity, pricing strategies, distribution networks, manufacturing capacity, and focus areas such as infectious diseases, chronic disease management, emergency care, and home diagnostics.
Geographic Analysis In-depth regional assessment of the global point-of-care diagnostics market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with analysis of healthcare infrastructure, disease burden, diagnostic accessibility, reimbursement landscape, regulatory environment, and decentralized testing adoption trends. Country-level market sizing, CAGR forecasts, epidemiological analysis, healthcare expenditure trends, regulatory landscape assessment, diagnostic penetration rates, reimbursement policies, and demand outlook across major markets such as the US, Germany, UK, China, India, Japan, Brazil, and GCC countries.

RECENT DEVELOPMENTS

  • January 2025 : Abbott continued expanding its Point of Care diagnostics portfolio with rapid diagnostic solutions for cardiometabolic, infectious disease, and emergency care applications.
  • May 2025 : Roche expanded its cobas liat point-of-care PCR testing portfolio to strengthen rapid decentralized infectious disease diagnostics.
  • February 2025 : Siemens Healthineers advanced its point-of-care diagnostics strategy by enhancing digitalized near-patient testing and workflow efficiency across healthcare settings.
  • June 2025 : QuidelOrtho announced the planned acquisition of LEX Diagnostics to strengthen its rapid point-of-care molecular diagnostics portfolio.
  • April 2025 : Danaher continued expanding its Cepheid and Radiometer businesses to strengthen rapid molecular and point-of-care diagnostic testing capabilities.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
48
2
EXECUTIVE SUMMARY
 
 
 
 
 
54
3
PREMIUM INSIGHTS
 
 
 
 
 
60
4
MARKET OVERVIEW
Explore booming opportunities in POC testing amid rising chronic diseases and decentralized healthcare trends.
 
 
 
 
 
64
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
GROWING INCIDENCE OF INFECTIOUS DISEASES
 
 
 
 
 
 
4.2.1.2
INCREASING PREVALENCE OF CHRONIC DISEASES
 
 
 
 
 
 
4.2.1.3
FAVORABLE GOVERNMENT INITIATIVES FOR POC TESTING
 
 
 
 
 
 
4.2.1.4
RISING NUMBER OF WAIVED TESTS
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
PRICING PRESSURE ON MANUFACTURERS
 
 
 
 
 
 
4.2.2.2
STRINGENT REGULATORY APPROVAL PROCESS FOR PRODUCT COMMERCIALIZATION
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
INCREASING GROWTH POTENTIAL IN EMERGING MARKETS
 
 
 
 
 
 
4.2.3.2
RISING INCLINATION TOWARD DECENTRALIZED HEALTHCARE SYSTEMS
 
 
 
 
 
 
4.2.3.3
BOOMING HEALTHCARE SPENDING WORLDWIDE
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
INADEQUATE STANDARDIZATION WITH CENTRALIZED LAB METHODS
 
 
 
 
 
 
4.2.4.2
PREMIUM PRICING OF NOVEL PLATFORMS
 
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
 
 
4.3.1
UNMET NEEDS IN POC DIAGNOSTICS MARKET
 
 
 
 
 
 
4.3.2
WHITE SPACE OPPORTUNITIES
 
 
 
 
 
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
 
4.4.1
INTERCONNECTED MARKETS
 
 
 
 
 
 
4.4.2
CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
 
 
 
 
 
 
 
4.5.1
KEY MOVES AND STRATEGIC FOCUS
 
 
 
 
5
INDUSTRY TRENDS
Navigate industry shifts with strategic insights from supply chain dynamics and competitive forces analysis.
 
 
 
 
 
80
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.2
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.3
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.4
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC INDICATORS
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
5.3
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.5
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
5.6
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.6.1
AVERAGE SELLING PRICE, BY PRODUCT
 
 
 
 
 
 
 
5.6.1.1
AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
 
 
 
 
 
5.6.2
AVERAGE SELLING PRICE, BY REGION
 
 
 
 
 
 
 
5.6.2.1
AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION
 
 
 
 
 
 
5.6.2.2
AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION
 
 
 
 
 
 
 
AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS,
 
 
 
 
5.7
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
5.9
IMPACT OF US TARIFFS—POC DIAGNOSTICS MARKET
 
 
 
 
 
 
 
 
5.9.1
INTRODUCTION
 
 
 
 
 
 
5.9.2
KEY TARIFF RATES
 
 
 
 
 
 
5.9.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.9.4
IMPACT ON COUNTRIES/REGIONS
 
 
 
 
 
 
 
5.9.4.1
NORTH AMERICA
 
 
 
 
 
 
5.9.4.2
EUROPE
 
 
 
 
 
 
5.9.4.3
ASIA PACIFIC
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations and patents reshape the future landscape of point-of-care diagnostics.
 
 
 
 
 
98
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1
IMMUNOASSAYS
 
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.2.1
MOLECULAR DIAGNOSTICS
 
 
 
 
 
6.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.3.1
BIOCHEMICAL TECHNOLOGIES
 
 
 
 
 
6.4
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.5
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.5.1
LIST OF MAJOR PATENTS
 
 
 
 
 
6.6
FUTURE APPLICATIONS
 
 
 
 
 
 
6.7
IMPACT OF AI/GENERATIVE AI ON POC DIAGNOSTICS MARKET
 
 
 
 
 
 
 
 
6.7.1
INTRODUCTION
 
 
 
 
 
 
6.7.2
TOP USE CASES AND MARKET POTENTIAL
 
 
 
 
 
 
6.7.3
KEY COMPANIES IMPLEMENTING AI
 
 
 
 
 
 
6.7.4
FUTURE OF AI
 
 
 
 
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
Navigate evolving global regulations and eco-friendly initiatives shaping POC diagnostics sustainability.
 
 
 
 
 
107
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
 
 
7.2
SUSTAINABILITY INITIATIVES
 
 
 
 
 
 
 
7.2.1
ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN POC DIAGNOSTICS
 
 
 
 
 
 
 
7.2.1.1
ECO-FRIENDLY INITIATIVES
 
 
 
 
7.3
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
 
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock revenue by understanding stakeholder influence and unmet needs across industries.
 
 
 
 
 
113
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.2.2
BUYING CRITERIA
 
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.4
UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
8.5
MARKET PROFITABILITY
 
 
 
 
 
 
 
8.5.1
REVENUE POTENTIAL
 
 
 
 
 
 
8.5.2
COST DYNAMICS
 
 
 
 
 
 
8.5.3
MARGIN OPPORTUNITIES IN KEY APPLICATIONS
 
 
 
 
9
POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 31 Data Tables
 
 
 
 
 
119
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
BIOCHEMISTRY
 
 
 
 
 
 
 
9.2.1
INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
 
 
 
 
 
9.3
IMMUNOASSAYS
 
 
 
 
 
 
 
9.3.1
GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
 
 
 
 
 
9.4
MOLECULAR DIAGNOSTICS
 
 
 
 
 
 
 
9.4.1
RT-PCR
 
 
 
 
 
 
 
9.4.1.1
GROWING USE OF RT-PCR IN PROTEOMICS AND GENOMICS TO BOOST MARKET
 
 
 
 
 
9.4.2
INAAT
 
 
 
 
 
 
 
9.4.2.1
EMERGING NEW PATHOGENS TO FACILITATE GROWTH
 
 
 
10
POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 25 Data Tables
 
 
 
 
 
135
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
BLOOD SAMPLES
 
 
 
 
 
 
 
10.2.1
GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
 
 
 
 
 
10.3
NASAL & OROPHARYNGEAL SWABS
 
 
 
 
 
 
 
10.3.1
INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
 
 
 
 
 
10.4
URINE SAMPLES
 
 
 
 
 
 
 
10.4.1
NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
 
 
 
 
 
10.5
OTHER SAMPLES
 
 
 
 
 
11
POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 13 Data Tables
 
 
 
 
 
150
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
PRESCRIPTION-BASED TESTING PRODUCTS
 
 
 
 
 
 
 
11.2.1
RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
 
 
 
 
 
11.3
OTC TESTING PRODUCTS
 
 
 
 
 
 
 
11.3.1
GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
 
 
 
 
12
POINT OF CARE DIAGNOSTICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 26 Data Tables
 
 
 
 
 
159
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
CLINICAL LABORATORIES
 
 
 
 
 
 
 
12.2.1
GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
 
 
 
 
 
12.3
HOME CARE SETTINGS & SELF-TESTING
 
 
 
 
 
 
 
12.3.1
INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
 
 
 
 
 
12.4
HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
 
 
 
 
 
 
 
12.4.1
RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
 
 
 
 
 
12.5
AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES
 
 
 
 
 
 
 
12.5.1
NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
 
 
 
 
 
12.6
OTHER END USERS
 
 
 
 
 
13
POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 243 Data Tables
 
 
 
 
 
174
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
GLUCOSE MONITORING PRODUCTS
 
 
 
 
 
 
 
13.2.1
GLUCOSE MONITORING STRIPS
 
 
 
 
 
 
 
13.2.1.1
GROWING TREND TOWARD PREVENTIVE HEALTHCARE TO DRIVE MARKET
 
 
 
 
 
13.2.2
GLUCOSE MONITORING METERS
 
 
 
 
 
 
 
13.2.2.1
GROWING TECHNOLOGICAL ADVANCEMENTS IN GLUCOSE METERS TO PROPEL MARKET
 
 
 
 
 
13.2.3
GLUCOSE MONITORING LANCETS & LANCING DEVICES
 
 
 
 
 
 
 
13.2.3.1
INCREASING TENDENCY FOR HOME-BASED CARE AND SELF-MONITORING TO AID GROWTH
 
 
 
 
13.3
CARDIOMETABOLIC TESTING PRODUCTS
 
 
 
 
 
 
 
13.3.1
CARDIAC MARKER TESTING PRODUCTS
 
 
 
 
 
 
 
13.3.1.1
GROWING GOVERNMENT SUPPORT FOR CARDIOVASCULAR DISEASES TO DRIVE MARKET
 
 
 
 
 
13.3.2
BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
 
 
 
 
 
 
 
13.3.2.1
NEED TO OPTIMIZE HOSPITAL WORKFLOW TO FAVOR GROWTH
 
 
 
 
 
13.3.3
HBA1C TESTING PRODUCTS
 
 
 
 
 
 
 
13.3.3.1
INCREASING RECOMMENDATIONS BY GOVERNMENT HEALTHCARE AUTHORITIES TO BOOST MARKET
 
 
 
 
13.4
INFECTIOUS DISEASE TESTING PRODUCTS
 
 
 
 
 
 
 
13.4.1
RESPIRATORY INFECTION TESTING PRODUCTS
 
 
 
 
 
 
 
13.4.1.1
INFLUENZA TESTING PRODUCTS
 
 
 
 
 
 
 
 
13.4.1.1.1
NEED FOR TARGETED TREATMENTS TO EXPEDITE GROWTH
 
 
 
 
13.4.1.2
TUBERCULOSIS TESTING PRODUCTS
 
 
 
 
 
 
 
 
13.4.1.2.1
INCREASING DEMAND FOR DIAGNOSTIC PRODUCTS AND SERVICES TO CONTRIBUTE TO GROWTH
 
 
 
 
13.4.1.3
OTHER RESPIRATORY INFECTION TESTING PRODUCTS
 
 
 
 
 
13.4.2
HAI TESTING PRODUCTS
 
 
 
 
 
 
 
13.4.2.1
GROWING RATE OF SURGICAL-SITE INFECTIONS TO BOOST MARKET
 
 
 
 
 
13.4.3
TROPICAL DISEASE TESTING PRODUCTS
 
 
 
 
 
 
 
13.4.3.1
RISING INCIDENCE OF MALARIA AND DENGUE TO SUPPORT GROWTH
 
 
 
 
 
13.4.4
STD TESTING PRODUCTS
 
 
 
 
 
 
 
13.4.4.1
HIV TESTING PRODUCTS
 
 
 
 
 
 
 
 
13.4.4.1.1
GROWING AVAILABILITY AND AWARENESS OF TESTING PRODUCTS TO BOOST MARKET
 
 
 
 
13.4.4.2
HEPATITIS TESTING PRODUCTS
 
 
 
 
 
 
 
 
13.4.4.2.1
HEPATITIS B TESTING PRODUCTS
 
 
 
 
 
 
13.4.4.2.2
HEPATITIS C TESTING PRODUCTS
 
 
 
 
13.4.4.3
SYPHILIS TESTING PRODUCTS
 
 
 
 
 
 
 
 
13.4.4.3.1
NEED FOR EARLY AND ACCESSIBLE DIAGNOSIS TO EXPEDITE GROWTH
 
 
 
 
13.4.4.4
HUMAN PAPILLOMAVIRUS TESTING PRODUCTS
 
 
 
 
 
 
 
 
13.4.4.4.1
RISING CASES OF CERVICAL CANCER TO PROMOTE GROWTH
 
 
 
 
13.4.4.5
CHLAMYDIA TRACHOMATIS TESTING PRODUCTS
 
 
 
 
 
 
 
 
13.4.4.5.1
GROWING ADOPTION OF ADVANCED TECHNIQUES TO DRIVE MARKET
 
 
 
 
13.4.4.6
NEISSERIA GONORRHEA TESTING PRODUCTS
 
 
 
 
 
 
 
 
13.4.4.6.1
RISING INCIDENCE OF GONORRHEA AND ANTIMICROBIAL RESISTANCE TO AUGMENT GROWTH
 
 
 
 
13.4.4.7
HSV TESTING PRODUCTS
 
 
 
 
 
 
 
 
13.4.4.7.1
INCREASING INCIDENCE OF HERPES TO SUPPORT GROWTH
 
 
 
13.4.5
CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
 
 
 
 
 
 
 
13.4.5.1
RISING CASES AMONG HOSPITALIZED PATIENTS TO BOOST DEMAND
 
 
 
 
 
13.4.6
OTHER INFECTIOUS DISEASE TESTING PRODUCTS
 
 
 
 
 
13.5
COAGULATION MONITORING PRODUCTS
 
 
 
 
 
 
 
13.5.1
NEED FOR REGULAR MONITORING AND RISING DEMAND FOR HOME-USE KITS TO PROPEL MARKET
 
 
 
 
 
 
13.5.2
PT/INR TESTING PRODUCTS
 
 
 
 
 
 
 
13.5.2.1
INCREASING NUMBER OF ATRIAL FIBRILLATION CASES TO ACCELERATE GROWTH
 
 
 
 
 
13.5.3
ACT/APTT TESTING PRODUCTS
 
 
 
 
 
 
 
13.5.3.1
RISE IN SURGICAL PROCEDURES TO SPEED UP GROWTH
 
 
 
 
13.6
PREGNANCY & FERTILITY TESTING PRODUCTS
 
 
 
 
 
 
 
13.6.1
PREGNANCY TESTING PRODUCTS
 
 
 
 
 
 
 
13.6.1.1
INCREASING AWARENESS ABOUT FAMILY PLANNING TO STIMULATE GROWTH
 
 
 
 
 
13.6.2
FERTILITY TESTING PRODUCTS
 
 
 
 
 
 
 
13.6.2.1
GROWING INFERTILITY ISSUES TO FUEL MARKET
 
 
 
 
13.7
TUMOR/CANCER MARKER TESTING PRODUCTS
 
 
 
 
 
 
 
13.7.1
GROWING CANCER INCIDENCE AND GOVERNMENT SUPPORT FOR CANCER MANAGEMENT AND THERAPIES DRIVE MARKET
 
 
 
 
 
13.8
URINALYSIS TESTING PRODUCTS
 
 
 
 
 
 
 
13.8.1
INCREASING DEMAND FOR RAPID POC TESTING TECHNOLOGIES TO SUPPORT MARKET GROWTH
 
 
 
 
 
13.9
CHOLESTEROL TESTING PRODUCTS
 
 
 
 
 
 
 
13.9.1
GROWING GERIATRIC POPULATION AND RISING OBESITY LEVELS TO DRIVE MARKET
 
 
 
 
 
13.10
HEMATOLOGY TESTING PRODUCTS
 
 
 
 
 
 
 
13.10.1
RAPID DIAGNOSTICS AND MONITORING SUPPORT TO PROPEL END-USER ADOPTION
 
 
 
 
 
13.11
DRUGS-OF-ABUSE TESTING PRODUCTS
 
 
 
 
 
 
 
13.11.1
GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
 
 
 
 
 
13.12
THYROID-STIMULATING HORMONE TESTING PRODUCTS
 
 
 
 
 
 
 
13.12.1
GROWING PREVALENCE OF THYROID DISORDERS DRIVING DEMAND FOR TSH TESTING PRODUCTS
 
 
 
 
 
13.13
FECAL OCCULT TESTING PRODUCTS
 
 
 
 
 
 
 
13.13.1
GROWING INCIDENCE OF CANCER TO PROPEL THE MARKET
 
 
 
 
 
13.14
OTHER PRODUCTS
 
 
 
 
 
14
POINT OF CARE DIAGNOSTICS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 14 Countries | 317 Data Tables.
 
 
 
 
 
287
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
NORTH AMERICA
 
 
 
 
 
 
 
14.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
14.2.2
US
 
 
 
 
 
 
 
14.2.2.1
PRESENCE OF ADVANCED HEALTHCARE INFRASTRUCTURE AND HIGH HEALTHCARE EXPENDITURE TO AID GROWTH
 
 
 
 
 
14.2.3
CANADA
 
 
 
 
 
 
 
14.2.3.1
RISING INCIDENCE OF DIABETES AND INFECTIOUS DISEASES TO SUPPORT GROWTH
 
 
 
 
14.3
EUROPE
 
 
 
 
 
 
 
14.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
14.3.2
GERMANY
 
 
 
 
 
 
 
14.3.2.1
INCREASING NEED FOR RAPID AND ACCURATE DIAGNOSTIC SOLUTIONS TO PROMOTE GROWTH
 
 
 
 
 
14.3.3
FRANCE
 
 
 
 
 
 
 
14.3.3.1
GROWING DEMAND FOR ACCESSIBLE AND CONVENIENT DIAGNOSTIC TOOLS TO PROPEL MARKET
 
 
 
 
 
14.3.4
UK
 
 
 
 
 
 
 
14.3.4.1
RISING NUMBER OF ACCREDITED CLINICAL AND HOSPITAL LABORATORIES TO SUSTAIN GROWTH
 
 
 
 
 
14.3.5
ITALY
 
 
 
 
 
 
 
14.3.5.1
GROWING BURDEN OF INFECTIOUS AND PARASITIC DISEASES TO BOOST MARKET
 
 
 
 
 
14.3.6
SPAIN
 
 
 
 
 
 
 
14.3.6.1
RISING PREVALENCE OF CIRCULATORY SYSTEM DISEASES TO CONTRIBUTE TO GROWTH
 
 
 
 
 
14.3.7
REST OF EUROPE
 
 
 
 
 
14.4
ASIA PACIFIC
 
 
 
 
 
 
 
14.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
14.4.2
CHINA
 
 
 
 
 
 
 
14.4.2.1
INCREASING IMPACT OF DIABETES ON PUBLIC HEALTH TO AMPLIFY GROWTH
 
 
 
 
 
14.4.3
JAPAN
 
 
 
 
 
 
 
14.4.3.1
BOOMING GERIATRIC POPULATION TO STIMULATE GROWTH
 
 
 
 
 
14.4.4
INDIA
 
 
 
 
 
 
 
14.4.4.1
INCREASING CASES OF CHRONIC HEART AND KIDNEY DISEASES TO FOSTER GROWTH
 
 
 
 
 
14.4.5
AUSTRALIA
 
 
 
 
 
 
 
14.4.5.1
GROWING RESEARCH INVESTMENTS FOR NEXT-GEN POC DEVICES TO BOOST MARKET
 
 
 
 
 
14.4.6
SOUTH KOREA
 
 
 
 
 
 
 
14.4.6.1
GROWING FOCUS ON INNOVATIVE DIAGNOSTIC PRODUCTS TO DRIVE MARKET
 
 
 
 
 
14.4.7
REST OF ASIA PACIFIC
 
 
 
 
 
14.5
LATIN AMERICA
 
 
 
 
 
 
 
14.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
14.5.2
BRAZIL
 
 
 
 
 
 
 
14.5.2.1
INCREASING PUBLIC INITIATIVES IN HEALTHCARE TO ENCOURAGE GROWTH
 
 
 
 
 
14.5.3
MEXICO
 
 
 
 
 
 
 
14.5.3.1
NEED FOR FREQUENT TESTING FOR DISEASE MANAGEMENT TO EXPEDITE GROWTH
 
 
 
 
 
14.5.4
REST OF LATIN AMERICA
 
 
 
 
 
14.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
14.6.1
GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
 
 
 
 
 
 
14.6.2
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
15
COMPETITIVE LANDSCAPE
Gain insights into market leaders' strategies and competitive positioning in POC diagnostics.
 
 
 
 
 
426
 
15.1
INTRODUCTION
 
 
 
 
 
 
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
 
15.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POC DIAGNOSTICS MARKET
 
 
 
 
 
15.3
REVENUE ANALYSIS, 2023–2025
 
 
 
 
 
 
 
15.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
15.5
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
 
 
15.6
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
 
15.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
 
 
 
 
 
 
 
 
15.7.1
STARS
 
 
 
 
 
 
15.7.2
EMERGING LEADERS
 
 
 
 
 
 
15.7.3
PERVASIVE PLAYERS
 
 
 
 
 
 
15.7.4
PARTICIPANTS
 
 
 
 
 
 
15.7.5
COMPANY FOOTPRINT, KEY PLAYERS, 2025
 
 
 
 
 
 
 
15.7.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
15.7.5.2
REGION FOOTPRINT
 
 
 
 
 
 
15.7.5.3
MODE OF PURCHASE FOOTPRINT
 
 
 
 
 
 
15.7.5.4
TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
15.7.5.5
SAMPLE FOOTPRINT
 
 
 
 
15.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
 
 
 
 
 
 
 
 
15.8.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
15.8.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
15.8.3
DYNAMIC COMPANIES
 
 
 
 
 
 
15.8.4
STARTING BLOCKS
 
 
 
 
 
 
15.8.5
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
 
 
 
 
 
 
 
15.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
15.8.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
15.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
15.9.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
445
 
16.1
KEY PLAYERS
 
 
 
 
 
 
 
16.1.1
ABBOTT
 
 
 
 
 
 
 
16.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
16.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
16.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
16.1.1.3.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
 
 
16.1.1.3.2
DEALS
 
 
 
 
16.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
16.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
16.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
16.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
 
 
 
16.1.2
F. HOFFMANN-LA ROCHE LTD
 
 
 
 
 
 
16.1.3
SIEMENS HEALTHINEERS AG
 
 
 
 
 
 
16.1.4
QUIDELORTHO CORPORATION
 
 
 
 
 
 
16.1.5
DANAHER
 
 
 
 
 
 
16.1.6
WERFEN
 
 
 
 
 
 
16.1.7
BD
 
 
 
 
 
 
16.1.8
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
16.1.9
BIOMÉRIEUX
 
 
 
 
 
 
16.1.10
EKF DIAGNOSTICS HOLDINGS PLC
 
 
 
 
 
 
16.1.11
TRINITY BIOTECH
 
 
 
 
 
 
16.1.12
ORASURE TECHNOLOGIES, INC.
 
 
 
 
 
 
16.1.13
GRIFOLS S.A.
 
 
 
 
 
 
16.1.14
QIAGEN
 
 
 
 
 
16.2
OTHER PLAYERS
 
 
 
 
 
 
 
16.2.1
NOVA BIOMEDICAL
 
 
 
 
 
 
16.2.2
SEKISUI DIAGNOSTICS
 
 
 
 
 
 
16.2.3
SEKISUI DIAGNOSTICS
 
 
 
 
 
 
16.2.4
LIFESCAN IP HOLDINGS, LLC
 
 
 
 
 
 
16.2.5
PTS DIAGNOSTICS
 
 
 
 
 
 
16.2.6
EUROLYSER DIAGNOSTICA GMBH
 
 
 
 
 
 
16.2.7
RESPONSE BIOMEDICAL
 
 
 
 
 
 
16.2.8
ALFA SCIENTIFIC DESIGNS, INC.
 
 
 
 
 
 
16.2.9
BTNX INC.
 
 
 
 
 
 
16.2.10
ASCENSIA DIABETES CARE HOLDINGS AG
 
 
 
 
 
 
16.2.11
FLUXERGY
 
 
 
 
 
 
16.2.12
PRECISION BIOSENSOR, INC.
 
 
 
 
 
 
16.2.13
ACON LABORATORIES, INC.
 
 
 
 
 
 
16.2.14
MENARINI DIAGNOSTICS S.R.L
 
 
 
 
 
 
16.2.15
MANKIND PHARMA
 
 
 
 
17
RESEARCH METHODOLOGY
 
 
 
 
 
526
 
17.1
RESEARCH DATA
 
 
 
 
 
 
17.2
RESEARCH APPROACH
 
 
 
 
 
 
 
17.2.1
SECONDARY RESEARCH
 
 
 
 
 
 
 
17.2.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
17.2.2
PRIMARY DATA
 
 
 
 
 
 
 
17.2.2.1
PRIMARY SOURCES
 
 
 
 
 
 
17.2.2.2
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
 
 
17.2.2.3
KEY INDUSTRY INSIGHTS
 
 
 
 
17.3
MARKET SIZE ESTIMATION
 
 
 
 
 
 
 
17.3.1
BOTTOM-UP APPROACH
 
 
 
 
 
 
 
17.3.1.1
APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
 
 
 
 
 
 
17.3.1.2
APPROACH 2: PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
 
 
 
 
 
 
17.3.1.3
GROWTH FORECAST
 
 
 
 
 
17.3.2
TOP-DOWN APPROACH
 
 
 
 
 
17.4
MARKET BREAKDOWN AND DATA TRIANGULATION
 
 
 
 
 
 
17.5
MARKET SHARE ANALYSIS
 
 
 
 
 
 
 
17.6
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
 
17.6.1
PARAMETRIC ASSUMPTIONS
 
 
 
 
 
 
17.6.2
GROWTH RATE ASSUMPTIONS
 
 
 
 
 
17.7
RESEARCH LIMITATIONS
 
 
 
 
 
 
17.8
RISK ASSESSMENT
 
 
 
 
 
18
APPENDIX
 
 
 
 
 
539
 
18.1
DISCUSSION GUIDE
 
 
 
 
 
 
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
18.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
18.4
RELATED REPORTS
 
 
 
 
 
 
18.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
 
PROJECTED INCREASE OF CANCER PATIENTS, BY REGION,
 
 
 
 
 
 
2025
VS. 2035 VS. 2045
 
 
 
 
 
67
 
GLOBAL DIABETES ESTIMATES (AGES 20–79) BY REGION,
 
 
 
 
 
 
2024
VS. 2030 VS. 2045 (IN THOUSANDS)
 
 
 
 
 
68
TABLE 3
PRODUCT WAIVERS, BY KEY PLAYER, 2021–2026
 
 
 
 
 
 
TABLE 4
POC DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 5
GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2024–2031
 
 
 
 
 
 
TABLE 6
NORTH AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 7
EUROPE: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 8
ASIA PACIFIC: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 9
LATIN AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 10
MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 11
POC DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
 
 
TABLE 12
AVERAGE SELLING PRICE OF POC TESTS, BY PRODUCT, 2023–2025
 
 
 
 
 
 
TABLE 13
AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2023–2025
 
 
 
 
 
 
TABLE 14
AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2023–2025
 
 
 
 
 
 
TABLE 15
AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2023–2025
 
 
 
 
 
 
TABLE 16
AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2023–2025
 
 
 
 
 
 
TABLE 17
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 18
LIST OF MAJOR PATENTS PERTAINING TO POC DIAGNOSTICS MARKET, 2023–2025
 
 
 
 
 
 
TABLE 19
KEY COMPANIES IMPLEMENTING AI IN POC DIAGNOSTICS MARKET
 
 
 
 
 
 
TABLE 20
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 21
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 22
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 23
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 24
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 25
GLOBAL STANDARDS IN POC DIAGNOSTICS MARKET
 
 
 
 
 
 
TABLE 26
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
 
 
 
 
 
 
TABLE 27
KEY BUYING CRITERIA, BY TECHNOLOGY
 
 
 
 
 
 
TABLE 28
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
TABLE 29
POC DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
TABLE 30
POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 31
KEY BIOCHEMISTRY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 32
POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 33
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 34
EUROPE: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 35
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
KEY IMMUNOASSAY-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 38
POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
EUROPE: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
KEY RT-PCR-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 50
POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
KEY INAAT-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 56
POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
NORTH AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
EUROPE: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
ASIA PACIFIC: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
LATIN AMERICA: POC MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 62
KEY BLOOD SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 63
POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
EUROPE: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 66
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 68
KEY NASAL AND OROPHARYNGEAL SWAB-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 69
POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
EUROPE: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 72
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
KEY URINE SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 75
POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
EUROPE: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
KEY OTHER SAMPLE-BASED POC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 81
POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
EUROPE: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 88
POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 90
EUROPE: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 94
POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
EUROPE: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
EUROPE: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
EUROPE: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOME CARE SETTINGS & SELF-TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
EUROPE: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, B Y COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
EUROPE: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIAN OFFICES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 121
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
EUROPE: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
POC GLUCOSE MONITORING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 131
LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 133
GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
NORTH AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
EUROPE: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
ASIA PACIFIC: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
LATIN AMERICA: GLUCOSE MONITORING STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 139
GLUCOSE MONITORING METERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
NORTH AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
EUROPE: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
ASIA PACIFIC: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
LATIN AMERICA: GLUCOSE MONITORING METERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 145
GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
NORTH AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
EUROPE: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
ASIA PACIFIC: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
LATIN AMERICA: GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
KEY CARDIOMETABOLIC TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 151
POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
NORTH AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
EUROPE: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
ASIA PACIFIC: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 156
LATIN AMERICA: POC CARDIOMETABOLIC TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 157
CARDIAC MARKER TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
NORTH AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
EUROPE: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
ASIA PACIFIC: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
LATIN AMERICA: CARDIAC MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 163
NORTH AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
EUROPE: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY REGION, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 165
ASIA PACIFIC: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
LATIN AMERICA: BLOOD GAS/ELECTROLYTE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
HBA1C TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
NORTH AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 169
EUROPE: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
ASIA PACIFIC: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
LATIN AMERICA: HBA1C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 175
EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
NORTH AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 181
EUROPE: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
ASIA PACIFIC: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
LATIN AMERICA: RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 185
INFLUENZA TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
NORTH AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 187
EUROPE: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
ASIA PACIFIC: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
LATIN AMERICA: INFLUENZA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 191
TUBERCULOSIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
NORTH AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 193
EUROPE: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
ASIA PACIFIC: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
LATIN AMERICA: TUBERCULOSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 197
OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
NORTH AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
EUROPE: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
ASIA PACIFIC: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
LATIN AMERICA: OTHER RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
KEY HAI TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 203
HAI TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
NORTH AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
EUROPE: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
ASIA PACIFIC: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
LATIN AMERICA: HAI TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 209
TROPICAL DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 210
NORTH AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 211
EUROPE: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
ASIA PACIFIC: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
LATIN AMERICA: TROPICAL DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
STD TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
NORTH AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
EUROPE: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
ASIA PACIFIC: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
LATIN AMERICA: STD TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 221
HIV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
NORTH AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
EUROPE: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
ASIA PACIFIC: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
LATIN AMERICA: HIV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
HEPATITIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
NORTH AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
EUROPE: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
ASIA PACIFIC: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
LATIN AMERICA: HEPATITIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 233
HEPATITIS B TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
NORTH AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
EUROPE: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
ASIA PACIFIC: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
LATIN AMERICA: HEPATITIS B TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 239
HEPATITIS C TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
NORTH AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
EUROPE: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
ASIA PACIFIC: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
LATIN AMERICA: HEPATITIS C TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 245
SYPHILIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
NORTH AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
EUROPE: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
ASIA PACIFIC: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
LATIN AMERICA: SYPHILIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 251
HPV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
NORTH AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
EUROPE: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
ASIA PACIFIC: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
LATIN AMERICA: HPV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 257
CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
NORTH AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
EUROPE: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
ASIA PACIFIC: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
LATIN AMERICA: CHLAMYDIA TRACHOMATIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
NORTH AMERICA: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
EUROPE: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
ASIA PACIFIC: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
LATIN AMERICA: NEISSERIA GONORRHEA TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 268
HSV TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
NORTH AMERICA: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
EUROPE: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
ASIA PACIFIC: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
LATIN AMERICA: HSV TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 274
CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
NORTH AMERICA: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
EUROPE: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
ASIA PACIFIC: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 278
LATIN AMERICA: CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 280
OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
NORTH AMERICA: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
EUROPE: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
ASIA PACIFIC: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
LATIN AMERICA: OTHER INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
POC COAGULATION MONITORING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
NORTH AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
PT/INR TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
NORTH AMERICA: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
EUROPE: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
ASIA PACIFIC: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
LATIN AMERICA: PT/INR TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
ACT/APTT TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
NORTH AMERICA: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
EUROPE: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
ASIA PACIFIC: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
LATIN AMERICA: ACT/APTT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
NORTH AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 308
PREGNANCY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
NORTH AMERICA: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
EUROPE: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
ASIA PACIFIC: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
LATIN AMERICA: PREGNANCY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 314
FERTILITY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
NORTH AMERICA: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
EUROPE: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
ASIA PACIFIC: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
LATIN AMERICA: FERTILITY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
TYPES OF CANCER CASES WORLDWIDE, 2024VS. 2045
 
 
 
 
 
 
TABLE 320
KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 321
POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
NORTH AMERICA: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
EUROPE: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
ASIA PACIFIC: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
LATIN AMERICA: POC TUMOR/CANCER MARKER TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 327
POC URINALYSIS TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
NORTH AMERICA: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
EUROPE: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
ASIA PACIFIC: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
LATIN AMERICA: POC URINALYSIS TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 333
POC CHOLESTEROL TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
NORTH AMERICA: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
EUROPE: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
ASIA PACIFIC: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
LATIN AMERICA: POC CHOLESTEROL TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 339
POC HEMATOLOGY TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
NORTH AMERICA: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
EUROPE: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 342
ASIA PACIFIC: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
LATIN AMERICA: POC HEMATOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 345
POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
NORTH AMERICA: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
EUROPE: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
ASIA PACIFIC: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
LATIN AMERICA: POC DRUGS-OF-ABUSE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
KEY THYROID-STIMULATING HORMONE TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 351
POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
NORTH AMERICA: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
EUROPE: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
ASIA PACIFIC: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
LATIN AMERICA: POC THYROID-STIMULATING HORMONE TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 357
POC FECAL OCCULT TESTING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
NORTH AMERICA: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
EUROPE: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
ASIA PACIFIC: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
LATIN AMERICA: POC FECAL OCCULT TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
OTHER KEY POC DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
 
 
 
 
 
 
TABLE 363
OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
NORTH AMERICA: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
EUROPE: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
ASIA PACIFIC: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
LATIN AMERICA: OTHER POC DIAGNOSTIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
POC DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
NORTH AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 370
NORTH AMERICA: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
NORTH AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
NORTH AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
NORTH AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
NORTH AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
NORTH AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
NORTH AMERICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
NORTH AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
NORTH AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
NORTH AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
NORTH AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
NORTH AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
NORTH AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
NORTH AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
NORTH AMERICA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
US: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
US: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
US: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
US: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
US: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
US: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
US: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
US: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
US: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 394
US: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 395
US: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 396
US: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 397
US: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 398
US: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 399
CANADA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 400
CANADA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 401
CANADA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 402
CANADA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 403
CANADA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 404
CANADA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 405
CANADA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 406
CANADA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 407
CANADA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 408
CANADA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 409
CANADA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 410
CANADA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 411
CANADA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 412
CANADA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 413
EUROPE: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 414
EUROPE: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 415
EUROPE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 416
EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 417
EUROPE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 418
EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 419
EUROPE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 420
EUROPE: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 421
EUROPE: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 422
EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 423
EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 424
EUROPE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 425
EUROPE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 426
EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 427
EUROPE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 428
EUROPE: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 429
GERMANY: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 430
GERMANY: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 431
GERMANY: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 432
GERMANY: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 433
GERMANY: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 434
GERMANY: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 435
GERMANY: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 436
GERMANY: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 437
GERMANY: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 438
GERMANY: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 439
GERMANY: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 440
GERMANY: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 441
GERMANY: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 442
GERMANY: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 443
FRANCE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 444
FRANCE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 445
FRANCE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 446
FRANCE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 447
FRANCE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 448
FRANCE: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 449
FRANCE: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 450
FRANCE: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 451
FRANCE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 452
FRANCE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 453
FRANCE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 454
FRANCE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 455
FRANCE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 456
FRANCE: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 457
UK: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 458
UK: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 459
UK: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 460
UK: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 461
UK: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 462
UK: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 463
UK: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 464
UK: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 465
UK: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 466
UK: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 467
UK: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 468
UK: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 469
UK: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 470
UK: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 471
ITALY: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 472
ITALY: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 473
ITALY: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 474
ITALY: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 475
ITALY: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 476
ITALY: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 477
ITALY: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 478
ITALY: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 479
ITALY: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 480
ITALY: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 481
ITALY: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 482
ITALY: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 483
ITALY: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 484
ITALY: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 485
SPAIN: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 486
SPAIN: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 487
SPAIN: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 488
SPAIN: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 489
SPAIN: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 490
SPAIN: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 491
SPAIN: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 492
SPAIN: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 493
SPAIN: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 494
SPAIN: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 495
SPAIN: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 496
SPAIN: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 497
SPAIN: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 498
SPAIN: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 499
REST OF EUROPE: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 500
REST OF EUROPE: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 501
REST OF EUROPE: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 502
REST OF EUROPE: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 503
REST OF EUROPE: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 504
REST OF EUROPE: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 505
REST OF EUROPE: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 506
REST OF EUROPE: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 507
REST OF EUROPE: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 508
REST OF EUROPE: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 509
REST OF EUROPE: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 510
REST OF EUROPE: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 511
REST OF EUROPE: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 512
REST OF EUROPE: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 513
ASIA PACIFIC: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 514
ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 515
ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 516
ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 517
ASIA PACIFIC: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 518
ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 519
ASIA PACIFIC: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 520
ASIA PACIFIC: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 521
ASIA PACIFIC: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 522
ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 523
ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 524
ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 525
ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 526
ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 527
ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 528
ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 529
CHINA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 530
CHINA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 531
CHINA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 532
CHINA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 533
CHINA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 534
CHINA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 535
CHINA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 536
CHINA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 537
CHINA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 538
CHINA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 539
CHINA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 540
CHINA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 541
CHINA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 542
CHINA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 543
JAPAN: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 544
JAPAN: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 545
JAPAN: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 546
JAPAN: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 547
JAPAN: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 548
JAPAN: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 549
JAPAN: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 550
JAPAN: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 551
JAPAN: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 552
JAPAN: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 553
JAPAN: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 554
JAPAN: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 555
JAPAN: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 556
JAPAN: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 557
INDIA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 558
INDIA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 559
INDIA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 560
INDIA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 561
INDIA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 562
INDIA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 563
INDIA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 564
INDIA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 565
INDIA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 566
INDIA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 567
INDIA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 568
INDIA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 569
INDIA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 570
INDIA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 571
AUSTRALIA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 572
AUSTRALIA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 573
AUSTRALIA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 574
AUSTRALIA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 575
AUSTRALIA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 576
AUSTRALIA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 577
AUSTRALIA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 578
AUSTRALIA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 579
AUSTRALIA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 580
AUSTRALIA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 581
AUSTRALIA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 582
AUSTRALIA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 583
AUSTRALIA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 584
AUSTRALIA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 585
SOUTH KOREA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 586
SOUTH KOREA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 587
SOUTH KOREA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 588
SOUTH KOREA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 589
SOUTH KOREA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 590
SOUTH KOREA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 591
SOUTH KOREA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 592
SOUTH KOREA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 593
SOUTH KOREA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 594
SOUTH KOREA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 595
SOUTH KOREA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 596
SOUTH KOREA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 597
SOUTH KOREA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 598
SOUTH KOREA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 599
REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 600
REST OF ASIA PACIFIC: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 601
REST OF ASIA PACIFIC: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 602
REST OF ASIA PACIFIC: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 603
REST OF ASIA PACIFIC: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 604
REST OF ASIA PACIFIC: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 605
REST OF ASIA PACIFIC: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 606
REST OF ASIA PACIFIC: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 607
REST OF ASIA PACIFIC: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 608
REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 609
REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 610
REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 611
REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 612
REST OF ASIA PACIFIC: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 613
LATIN AMERICA: MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 614
LATIN AMERICA: POC DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 615
LATIN AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 616
LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 617
LATIN AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 618
LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 619
LATIN AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 620
LATIN AMERICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 621
LATIN AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 622
LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 623
LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 624
LATIN AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 625
LATIN AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 626
LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 627
LATIN AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 628
LATIN AMERICA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 629
BRAZIL: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 630
BRAZIL: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 631
BRAZIL: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 632
BRAZIL: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 633
BRAZIL: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 634
BRAZIL: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 635
BRAZIL: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 636
BRAZIL: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 637
BRAZIL: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 638
BRAZIL: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 639
BRAZIL: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 640
BRAZIL: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 641
BRAZIL: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 642
BRAZIL: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 643
MEXICO: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 644
MEXICO: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 645
MEXICO: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 646
MEXICO: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 647
MEXICO: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 648
MEXICO: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 649
MEXICO: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 650
MEXICO: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 651
MEXICO: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 652
MEXICO: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 653
MEXICO: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 654
MEXICO: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 655
MEXICO: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 656
MEXICO: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 657
REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 658
REST OF LATIN AMERICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 659
REST OF LATIN AMERICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 660
REST OF LATIN AMERICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 661
REST OF LATIN AMERICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 662
REST OF LATIN AMERICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 663
REST OF LATIN AMERICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 664
REST OF LATIN AMERICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 665
REST OF LATIN AMERICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 666
REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 667
REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 668
REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 669
REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 670
REST OF LATIN AMERICA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 671
MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 672
MIDDLE EAST & AFRICA: POC GLUCOSE MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 673
MIDDLE EAST & AFRICA: POC CARDIOMETABOLIC MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 674
MIDDLE EAST & AFRICA: POC INFECTIOUS DISEASE TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 675
MIDDLE EAST & AFRICA: POC RESPIRATORY INFECTION TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 676
MIDDLE EAST & AFRICA: POC STD TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 677
MIDDLE EAST & AFRICA: POC HEPATITIS TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 678
MIDDLE EAST & AFRICA: POC COAGULATION MONITORING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 679
MIDDLE EAST & AFRICA: POC PREGNANCY & FERTILITY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 680
MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 681
MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 682
MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 683
MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY SAMPLE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 684
MIDDLE EAST & AFRICA: POC DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 685
OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 686
POC DIAGNOSTICS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 687
POC DIAGNOSTICS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 688
POC DIAGNOSTICS MARKET: MODE OF PURCHASE FOOTPRINT
 
 
 
 
 
 
TABLE 689
POC DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
TABLE 690
POC DIAGNOSTICS MARKET: SAMPLE FOOTPRINT
 
 
 
 
 
 
TABLE 691
POC DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 692
POC DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
 
 
 
 
 
 
TABLE 693
POC DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
 
 
 
 
 
 
TABLE 694
POC DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2026
 
 
 
 
 
 
TABLE 695
ABBOTT: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 696
ABBOTT: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 697
ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 698
ABBOTT: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 699
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 700
F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 701
F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 702
F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 703
F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 704
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 705
SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 706
SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 707
SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 708
SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 709
QUIDELORTHO CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 710
QUIDELORTHO CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 711
QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 712
QUIDELORTHO CORPORATION: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 713
QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 714
DANAHER: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 715
DANAHER: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 716
DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 717
DANAHER: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 718
DANAHER: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 719
WERFEN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 720
WERFEN: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 721
WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 722
WERFEN: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 723
WERFEN: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 724
BD: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 725
BD: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 726
BD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 727
BD: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 728
BD: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 729
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 730
THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 731
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 732
BIOMÉRIEUX: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 733
BIOMÉRIEUX: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 734
BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 735
BIOMÉRIEUX: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 736
EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 737
EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 738
EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 739
EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 740
EKF DIAGNOSTICS HOLDINGS PLC: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 741
TRINITY BIOTECH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 742
TRINITY BIOTECH: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 743
TRINITY BIOTECH: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 744
TRINITY BIOTECH: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 745
ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 746
ORASURE TECHNOLOGIES, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 747
ORASURE TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 748
ORASURE TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 749
GRIFOLS S.A.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 750
GRIFOLS S.A.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 751
GRIFOLS S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 752
QIAGEN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 753
QIAGEN: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 754
QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 755
QIAGEN: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 756
QIAGEN: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 757
NOVA BIOMEDICAL: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 758
NOVA BIOMEDICAL: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 759
NOVA BIOMEDICAL: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 760
NOVA BIOMEDICAL: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 761
SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 762
SEKISUI DIAGNOSTICS: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 763
SEKISUI DIAGNOSTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 764
SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 765
SEKISUI DIAGNOSTICS: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 766
SEKISUI DIAGNOSTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 767
LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 768
PTS DIAGNOSTICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 769
EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 770
RESPONSE BIOMEDICAL: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 771
ALFA SCIENTIFIC DESIGNS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 772
BTNX INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 773
ASCENSIA DIABETES CARE HOLDINGS AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 774
FLUXERGY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 775
PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 776
ACON LABORATORIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 777
MENARINI DIAGNOSTICS S.R.L: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 778
MANKIND PHARMA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 779
POC DIAGNOSTICS MARKET: RISK ASSESSMENT
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
POC DIAGNOSTICS MARKET SEGMENTATION
 
 
 
 
 
 
FIGURE 2
KEY INSIGHTS AND MARKET HIGHLIGHTS
 
 
 
 
 
 
FIGURE 3
GLOBAL POC DIAGNOSTICS MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 4
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN POC DIAGNOSTICS MARKET, 2023–2025
 
 
 
 
 
 
FIGURE 5
DISRUPTIVE TRENDS IMPACTING GROWTH OF POC DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 6
HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN POC DIAGNOSTICS MARKET, 2026-2031
 
 
 
 
 
 
FIGURE 7
ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 8
RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
 
 
 
 
 
 
FIGURE 9
GLUCOSE MONITORING PRODUCTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 10
PRESCRIPTION-BASED TESTING PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 11
BIOCHEMISTRY SEGMENT TO WITNESS LARGEST MARKET SHARE DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
BLOOD SAMPLES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 13
HOME CARE SETTINGS & SELF-TESTING SEGMENT TO HOLD LARGEST MARKET SHARE
 
 
 
 
 
 
FIGURE 14
ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 15
POC DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 16
REGIONAL INCIDENCE OF HIV, 2025
 
 
 
 
 
 
FIGURE 17
POC DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 18
POC DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 19
POC DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 20
INVESTMENT AND FUNDING SCENARIO, 2021–2024
 
 
 
 
 
 
FIGURE 21
POC DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 22
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN POC DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 23
PATENT ANALYSIS FOR POC DIAGNOSTICS
 
 
 
 
 
 
FIGURE 24
MARKET POTENTIAL OF AI IN POC DIAGNOSTICS MARKET
 
 
 
 
 
 
FIGURE 25
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY
 
 
 
 
 
 
FIGURE 26
KEY BUYING CRITERIA, BY TECHNOLOGY
 
 
 
 
 
 
FIGURE 27
NORTH AMERICA: POC DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 28
ASIA PACIFIC: POC DIAGNOSTICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 29
REVENUE ANALYSIS OF KEY PLAYERS IN POC DIAGNOSTICS MARKET 2023–2025
 
 
 
 
 
 
FIGURE 30
MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
 
 
 
 
 
 
FIGURE 31
EV/EBITDA OF KEY VENDORS, 2024
 
 
 
 
 
 
FIGURE 32
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
 
 
 
 
 
 
FIGURE 33
POC DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
FIGURE 34
POC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 35
POC DIAGNOSTICS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 36
POC DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 37
ABBOTT: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 38
F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 39
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 40
QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 41
DANAHER: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 42
WERFEN: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 43
BD: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 44
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 45
BIOMÉRIEUX: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 46
EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 47
TRINITY BIOTECH: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 48
ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 49
GRIFOLS S.A.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 50
QIAGEN: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 51
POC DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
 
 
 
 
 
 
FIGURE 52
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 
 
 
 
 
 
FIGURE 53
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 54
GLOBAL POC DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS
 
 
 
 
 
 
FIGURE 55
CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
 
 
 
 
 
 
FIGURE 56
TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 57
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 

 

Methodology

The study involved major activities to estimate the current market size of the Point of Care diagnostics market. Exhaustive secondary research was conducted to gather information on the market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the POC diagnostics market.

Secondary Research

This research study involved the extensive use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, white papers, and Companies House documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the POC diagnostics market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply- and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, VPs/Managing Directors, Marketing Heads/Directors, Sales Directors, Marketing/Sales Managers, Regional/Area Sales Managers, Export/Import Heads/Managers, and Other Market-Related Personnel from various companies and organizations operating in the POC diagnostics market. Primary sources from the demand side included Law Enforcement Agencies, Vice Presidents, C-level Executives, Department Heads, Enterprises, Individuals, Supply Management Teams of Hospitals, Clinic Personnel, and Laboratory Technicians.

Point of Care Diagnostics Market Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Other primary roles include sales, marketing, and product management.
Note 3: Companies are classified into tiers based on their total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the POC diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Point of Care Diagnostics Market Top Down and Bottom Up Approach

Data Triangulation

The entire market was split into two segments when the market size was determined. Data triangulation and market breakdown were used as needed to complete the market engineering process and derive precise statistics for all segments.

Approach for deriving the market size and estimating market growth:

Using secondary data from paid and unpaid sources, the market rankings for the major players were determined through a thorough analysis of their POC diagnostic sales. Due to data restrictions, the revenue share in certain cases was determined after a thorough analysis of the product portfolio of big corporations and their individual sales performance. This information was verified at each stage by in-depth interviews with professionals in the field.

Market Definition

Point-of-care (POC) diagnostics refers to diagnostic testing performed at or near the patient's location, delivering rapid and accurate results to support immediate clinical decision-making. The market includes products such as blood glucose monitoring systems, infectious disease tests, cardiac biomarker assays, coagulation testing, blood gas and electrolyte analyzers, molecular diagnostics, pregnancy and fertility tests, urinalysis, and other rapid diagnostic solutions, serving hospitals, clinical laboratories, physician offices, ambulatory care facilities, retail clinics, pharmacies, and home healthcare settings.

Key Stakeholders

  • Diagnostic device manufacturers
  • Reagent and consumable suppliers
  • Hospitals and clinical laboratories
  • Physician offices and ambulatory care centers
  • Pharmacies and home healthcare providers
  • Medical device distributors
  • Regulatory authorities
  • Government and public health agencies
  • Research organizations
  • Healthcare IT providers

Report Objectives

  • To describe, analyze, and forecast the POC diagnostics  market, by product, sample, mode of purchase, technology, end user, and region
  • To describe and forecast the POC diagnostics  market for key regions, namely, North America, Europe, the Asia Pacific, Latin America and Middle East, and Africa
  • To provide detailed information regarding drivers, restraints, opportunities, and challenges influencing the growth of the POC diagnostics  market
  • To strategically analyze the ecosystem, regulations, patenting trend, value chain, Porter’s five forces, and prices pertaining to the market under study
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
  • To profile key players and comprehensively analyze their market shares and core competencies2 in the POC diagnostics  market
  • To analyze competitive developments such as collaborations, acquisitions, product launches, expansions, and R&D activities in the POC diagnostics  market

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of each company

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific POC diagnostics market into Vietnam, New Zealand, and other markets.
  • Further breakdown of the Rest of Latin America POC diagnostics market into Colombia, Chile, Ecuador, and others.
  • Further breakdown of the Rest of Europe POC diagnostics market into Belgium, Russia, the Netherlands, Switzerland, and others.

 

Key Questions Addressed by the Report

What is the projected growth outlook for the global point of care diagnostics market through 2031?

The global point of care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at a CAGR of 8.8% during the forecast period. The market was valued at USD 19.38 billion in 2025, driven by increasing adoption of rapid and decentralized diagnostic solutions.

Which region is expected to register the highest growth rate in the point of care diagnostics market?

China is expected to register the highest CAGR of 11.1% during the forecast period in the point of care diagnostics market. The regional growth outlook highlights increasing adoption of point-of-care testing solutions across healthcare settings.

Which product segment dominated the point of care diagnostics market in 2025?

Glucose monitoring products held the largest share of the point of care diagnostics market, accounting for 34.8% of the market in 2025. The segment is a key product category covered in the point of care diagnostics market analysis.

What was the market size of home care settings and self-testing segment in 2025?

The home care settings and self-testing segment of the point of care diagnostics market was valued at USD 6,936.5 million in 2025. Increasing demand for convenient and patient-centric diagnostic solutions is supporting the adoption of home-based testing.

What technologies are covered in the point of care diagnostics market?

The point of care diagnostics market covers technologies including biochemistry and molecular diagnostics (MDx), including RT-PCR and INAAT technologies. The market analysis also covers products such as glucose monitoring, infectious disease diagnostics, and pregnancy testing solutions.

Who are the key players operating in the global point of care diagnostics market?

Key players profiled in the point of care diagnostics market include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, QuidelOrtho Corporation, Danaher, Becton, Dickinson and Company, Thermo Fisher Scientific, Inc., bioMérieux, QIAGEN, Werfen S.A, OraSure Technologies, Trinity Biotech, Grifols S.A, Nova Biomedical, Sekisui Diagnostics, Trividia Health, Sysmex Corporation, HemoCue, Bio-Rad Laboratories, Chembio Diagnostics, Johnson & Johnson, LifeScan, Ascensia Diabetes Care, ARKRAY, Sinocare, and Wondfo Biotech.

Which companies are recognized as star players in the point of care diagnostics market?

Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), and Becton, Dickinson and Company (BD) (US) were identified as Star Players due to their strong focus on innovation, extensive product portfolios, broad industry presence, and robust operational and financial capabilities.

Which startups and SMEs are emerging in the point of care diagnostics market?

Visby Medical (US), Cue Health (US), and Truvian Health (US) are among key startups and SMEs in the point of care diagnostics market due to their strong product portfolios and business strategies.

TABLE OF CONTENTS

METHODOLOGY
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Point of Care Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Point of Care Diagnostics Market

avtar

Dennis

Jul, 2026

After reviewing the Point of Care Diagnostics Market report, I found the breakdown of decentralized testing adoption across emergency care, home diagnostics, and chronic disease monitoring particularly useful for evaluating near-term commercialization opportunities..

avtar

Jerry

Jul, 2026

I filled out the form to better understand how the Point of Care Diagnostics Market is evolving with rapid antigen technologies and portable molecular platforms, especially in regions where lab infrastructure remains limited..

avtar

Tyler

Jul, 2026

The insights on reimbursement trends, device miniaturization, and competitive positioning in the Point of Care Diagnostics Market gave me a clearer perspective on how manufacturers are adapting their product strategies for faster clinical decision-making..

bottom banner
DMCA.com Protection Status
popup img